Natixis Investment Managers International Has $120,000 Stock Position in Exact Sciences Co. (NASDAQ:EXAS)

Natixis Investment Managers International grew its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 33.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,732 shares of the medical research company’s stock after buying an additional 430 shares during the quarter. Natixis Investment Managers International’s holdings in Exact Sciences were worth $120,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in EXAS. Nordea Investment Management AB grew its holdings in shares of Exact Sciences by 3.6% during the fourth quarter. Nordea Investment Management AB now owns 19,528 shares of the medical research company’s stock valued at $1,452,000 after buying an additional 670 shares during the last quarter. BKM Wealth Management LLC purchased a new position in Exact Sciences during the fourth quarter worth about $74,000. Raymond James & Associates boosted its holdings in Exact Sciences by 5.8% during the fourth quarter. Raymond James & Associates now owns 62,925 shares of the medical research company’s stock worth $4,655,000 after purchasing an additional 3,430 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in Exact Sciences by 36.7% during the fourth quarter. Assenagon Asset Management S.A. now owns 8,778 shares of the medical research company’s stock worth $649,000 after purchasing an additional 2,358 shares during the last quarter. Finally, Values First Advisors Inc. boosted its holdings in Exact Sciences by 21.9% during the fourth quarter. Values First Advisors Inc. now owns 12,973 shares of the medical research company’s stock worth $960,000 after purchasing an additional 2,329 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Exact Sciences Trading Up 1.1 %

Shares of NASDAQ:EXAS traded up $0.51 during trading hours on Thursday, hitting $48.36. 3,466,571 shares of the company’s stock traded hands, compared to its average volume of 2,629,320. Exact Sciences Co. has a 1 year low of $40.62 and a 1 year high of $99.56. The business has a fifty day moving average price of $45.65 and a 200-day moving average price of $56.96. The firm has a market capitalization of $8.92 billion, a P/E ratio of -36.64 and a beta of 1.22. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.64 and a quick ratio of 1.45.

Exact Sciences (NASDAQ:EXAS) last announced its earnings results on Wednesday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.50). Exact Sciences had a negative return on equity of 7.12% and a negative net margin of 9.48%. The business had revenue of $637.52 million during the quarter, compared to analyst estimates of $624.95 million. Equities analysts expect that Exact Sciences Co. will post -1.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on EXAS shares. Citigroup cut their price target on shares of Exact Sciences from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Jefferies Financial Group started coverage on Exact Sciences in a research report on Monday, June 3rd. They issued a “buy” rating and a $75.00 target price for the company. Evercore ISI reduced their price target on Exact Sciences from $80.00 to $72.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. The Goldman Sachs Group reduced their price target on Exact Sciences from $88.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, July 17th. Finally, Canaccord Genuity Group reduced their target price on Exact Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. Two research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Exact Sciences has a consensus rating of “Moderate Buy” and an average price target of $85.80.

Insider Buying and Selling at Exact Sciences

In related news, CEO Kevin T. Conroy sold 1,155 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total value of $69,473.25. Following the completion of the sale, the chief executive officer now owns 1,156,191 shares in the company, valued at $69,544,888.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 1,498 shares of company stock worth $90,105 over the last 90 days. Company insiders own 1.36% of the company’s stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.